Roche Holding AG / Bicycle Therapeutics plc

Multiple Immuno-Oncology Indications (Bicyclic Peptide Platform)

1.9M US cases/yr · $150.0B Global oncology therapeutics market 2020 · ~$1.73B Total deal BD value (up to ~$1.7B milestones + $30M upfront)

Disease Overview

The Roche/Genentech-Bicycle Therapeutics collaboration targets multiple immuno-oncology indications via Bicycle's bicyclic peptide (Bicycle) platform applied to T-cell modulators. Bicycles are constrained synthetic peptide molecules with antibody-like specificity and small-molecule pharmacokinetics, theoretically combining the affinity and selectivity of biologics with the tissue penetration, manufacturing simplicity, and oral or subcutaneous administration potential of small molecules. The U.S. solid tumor immuno-oncology population spans approximately 1.9M new cancer cases annually, with checkpoint-eligible populations across NSCLC (~236,000 cases), melanoma (~100,000), renal cell carcinoma (~80,000), HCC (~42,000), urothelial (~83,000), and head & neck (~67,000) representing the major commercial frontiers. The deal anchored on Bicycle's Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) platform, which uses a tumor antigen-binding bicycle (Nectin-4, EphA2, MT1-MMP, others) tethered to an immune cell agonist (CD137/4-1BB, NK cell engager) to drive tumor-localized immune activation. Genentech selected initial two undisclosed targets with options on additional targets via $10M expansion fees. WAC pricing benchmarks for IO biologics range $15K-25K per month, with checkpoint inhibitor combinations often exceeding $30K per month.

Competitive Landscape

The immuno-oncology competitive landscape relevant to Bicycle's TICA platform spans checkpoint inhibitors and immune-cell agonist modalities. PD-(L)1 checkpoint leaders include pembrolizumab/Keytruda (Merck), nivolumab/Opdivo (Bristol Myers Squibb), atezolizumab/Tecentriq (Roche), durvalumab/Imfinzi (AstraZeneca). LAG-3 (relatlimab/Opdualag, BMS), TIM-3, TIGIT (tiragolumab, Roche), and other novel checkpoints are emerging. Tumor-targeted immune cell agonist competitors to Bicycle include Pieris Pharmaceuticals' Anticalin-CD137 platform (PRS-343), Maverick Therapeutics' COBRA bispecific T-cell engager platform (acquired by Takeda 2021), Numab Therapeutics' multispecifics, IGM Biosciences' IgM bispecific T-cell engagers, and Janux Therapeutics' TRACTr/TRACIr platforms. Bicycle Therapeutics' wholly-owned BT5528 (EphA2-MMAE Bicycle Toxin Conjugate) and BT8009 (Nectin-4-MMAE BTC) reached Phase 1/2 oncology trials. Roche/Genentech, beyond the Bicycle collaboration, runs an integrated IO franchise spanning Tecentriq, tiragolumab (anti-TIGIT), and CEA-IL2v cytokine immunotherapy positioning the Bicycle deal as a platform-level capability extension. Antibody-drug conjugates (Enhertu/trastuzumab deruxtecan from Daiichi/AstraZeneca, Trodelvy/sacituzumab govitecan from Gilead, Padcev/enfortumab vedotin from Pfizer/Astellas) represent the dominant tumor-targeted payload modality the bicycle peptide format must compete against on payload delivery economics. Cytokine-anchored TICA modalities (Nektar's bempegaldesleukin, Roche/Bristol cytokine fusions) and CD137/4-1BB agonists (Pfizer's utomilumab, Bristol's urelumab) provide additional competitive context for tumor-localized immune cell agonism.